These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 37396501)

  • 1. Diabetes and Metabolic Disorders: Their Impact on Cardiovascular Events in Liver Transplant Patients.
    Di Cola S; Cusi G; Lapenna L; Gazda J; Fonte S; Mattana M; Mennini G; Pasqualetti P; Merli M
    Can J Gastroenterol Hepatol; 2023; 2023():2199193. PubMed ID: 37396501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-alcoholic fatty liver disease (NAFLD), metabolic syndrome and cardiovascular events in atrial fibrillation. A prospective multicenter cohort study.
    Pastori D; Sciacqua A; Marcucci R; Del Ben M; Baratta F; Violi F; Pignatelli P;
    Intern Emerg Med; 2021 Nov; 16(8):2063-2068. PubMed ID: 33713286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonalcoholic Fatty Liver Disease before Kidney Transplantation Correlates with New Onset Diabetes and Poor Metabolic Outcomes.
    Grupper A; Rabinowich A; Ben Shabat I; Tzadok R; Schwartz D; Schwartz IF; Goykhman Y; Kliuk Ben-Bassat O; Baruch R; Shashar M; Cohen-Hagai K; Katchman H
    Am J Nephrol; 2022; 53(8-9):636-645. PubMed ID: 36075195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic syndrome before liver transplantation: does it have an impact on post liver transplantation outcome?
    Herreras López J; Puchades L; Di Maira T; Cañada AJ; Maupoey J; López-Andújar R; Prieto Castillo M; Berenguer Haym M; Aguilera V
    Rev Esp Enferm Dig; 2022 Oct; 114(10):586-591. PubMed ID: 35045717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonalcoholic Fatty Liver Disease and Fibrosis Associated With Increased Risk of Cardiovascular Events in a Prospective Study.
    Baratta F; Pastori D; Angelico F; Balla A; Paganini AM; Cocomello N; Ferro D; Violi F; Sanyal AJ; Del Ben M
    Clin Gastroenterol Hepatol; 2020 Sep; 18(10):2324-2331.e4. PubMed ID: 31887443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of metabolic syndrome and cardiovascular risk after liver transplantation.
    Fatourou EM; Tsochatzis EA
    Lancet Gastroenterol Hepatol; 2019 Sep; 4(9):731-741. PubMed ID: 31387736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Framingham score, renal dysfunction, and cardiovascular risk in liver transplant patients.
    Di Maira T; Rubin A; Puchades L; Aguilera V; Vinaixa C; Garcia M; De Maria N; Villa E; Lopez-Andujar R; San Juan F; Montalva E; Perez J; Prieto M; Berenguer M
    Liver Transpl; 2015 Jun; 21(6):812-22. PubMed ID: 27396823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic Acidosis 1 Year Following Kidney Transplantation and Subsequent Cardiovascular Events and Mortality: An Observational Cohort Study.
    Djamali A; Singh T; Melamed ML; Stein JH; Aziz F; Parajuli S; Mohamed M; Garg N; Mandelbrot D; Wesson DE; Astor BC
    Am J Kidney Dis; 2019 Apr; 73(4):476-485. PubMed ID: 30704880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained Posttransplantation Diabetes Is Associated With Long-Term Major Cardiovascular Events Following Liver Transplantation.
    Roccaro GA; Goldberg DS; Hwang WT; Judy R; Thomasson A; Kimmel SE; Forde KA; Lewis JD; Yang YX
    Am J Transplant; 2018 Jan; 18(1):207-215. PubMed ID: 28640504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of metabolic syndrome and metabolic dysfunction-associated fatty liver disease on cardiovascular risk by the presence or absence of type 2 diabetes and according to sex.
    Matsubayashi Y; Fujihara K; Yamada-Harada M; Mitsuma Y; Sato T; Yaguchi Y; Osawa T; Yamamoto M; Kitazawa M; Yamada T; Kodama S; Sone H
    Cardiovasc Diabetol; 2022 Jun; 21(1):90. PubMed ID: 35655263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular morbidity and mortality after liver transplantation: The protective role of mycophenolate mofetil.
    D'Avola D; Cuervas-Mons V; Martí J; Ortiz de Urbina J; Lladó L; Jimenez C; Otero E; Suarez F; Rodrigo JM; Gómez MA; Fraga E; Lopez P; Serrano MT; Rios A; Fábrega E; Herrero JI
    Liver Transpl; 2017 Apr; 23(4):498-509. PubMed ID: 28160394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-transplant diabetes predicts atherosclerotic vascular events and cardiovascular mortality in liver transplant recipients: a long-term follow-up study.
    Gitto S; De Maria N; Marzi L; Magistri P; Falcini M; Vitale G; Olivieri T; Guerrini GP; Serra V; Forte P; Carrai P; De Simone P; Mega A; Zoller H; Piai G; Schepis F; Marocchi M; Villa E; Marra F; Andreone P; Di Benedetto F;
    Eur J Intern Med; 2020 Sep; 79():70-75. PubMed ID: 32616342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-transplant diabetes mellitus and preexisting liver disease - a bidirectional relationship affecting treatment and management.
    Cigrovski Berkovic M; Virovic-Jukic L; Bilic-Curcic I; Mrzljak A
    World J Gastroenterol; 2020 Jun; 26(21):2740-2757. PubMed ID: 32550751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic Dysfunction-Associated Fatty Liver Disease Predicts Long-term Mortality and Cardiovascular Disease.
    Moon JH; Kim W; Koo BK; Cho NH;
    Gut Liver; 2022 May; 16(3):433-442. PubMed ID: 34635626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular risk after orthotopic liver transplantation, a review of the literature and preliminary results of a prospective study.
    Pisano G; Fracanzani AL; Caccamo L; Donato MF; Fargion S
    World J Gastroenterol; 2016 Oct; 22(40):8869-8882. PubMed ID: 27833378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular and metabolic disease in the liver transplant recipient.
    Kim NG; Sharma A; Saab S
    Best Pract Res Clin Gastroenterol; 2020; 46-47():101683. PubMed ID: 33158470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. De novo metabolic syndrome after liver transplantation: a meta-analysis on cumulative incidence, risk factors, and outcomes.
    Lim WH; Tan C; Xiao J; Tan DJH; Ng CH; Yong JN; Fu C; Chan KE; Zeng RW; Ren YP; Goh XL; Chew N; Tseng M; Syn N; Mak LY; Fung J; Muthiah M; Siddiqui MS; Tan EXX
    Liver Transpl; 2023 Apr; 29(4):413-421. PubMed ID: 36724882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan.
    Yoneda M; Yamamoto T; Honda Y; Imajo K; Ogawa Y; Kessoku T; Kobayashi T; Nogami A; Higurashi T; Kato S; Hosono K; Saito S; Nakajima A
    J Gastroenterol; 2021 Nov; 56(11):1022-1032. PubMed ID: 34601620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of de novo post-transplant type 2 diabetes in patients undergoing liver transplant for non-alcoholic steatohepatitis.
    Stepanova M; Henry L; Garg R; Kalwaney S; Saab S; Younossi Z
    BMC Gastroenterol; 2015 Dec; 15():175. PubMed ID: 26666336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular morbidity and mortality is increased post-liver transplantation even in recipients with no pre-existing risk factors.
    De Luca L; Kalafateli M; Bianchi S; Alasaker N; Buzzetti E; Rodríguez-Perálvarez M; Thorburn D; O'Beirne J; Patch D; Leandro G; Westbrook R; Tsochatzis EA
    Liver Int; 2019 Aug; 39(8):1557-1565. PubMed ID: 31233663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.